Retrospective, Observational, Monocentric Study to Assess Efficacy and Safety of the Combination of an Hypomethylating Agent in Combination With Venetoclax for Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
Latest Information Update: 05 Sep 2022
At a glance
- Drugs Azacitidine (Primary) ; Decitabine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
Most Recent Events
- 14 Sep 2020 Planned primary completion date changed from 23 Jul 2020 to 16 Sep 2020.
- 14 Sep 2020 Planned End Date changed from 30 Aug 2020 to 30 Sep 2020.
- 02 Jul 2020 New trial record